The EPA announced a new process called Science Supporting EPA Decisions, which will offer a structured opportunity to conduct peer reviews of actions developed by EPA earlier in the rule making process.
This article was published in The Hill on Feb. 23, 2022. The Food and Drug Administration (FDA), my former employer,
DC) issued its first “guidelines” for safely prescribing opioid pain medications, I was cooking breakfast when I burnt my finger on some very hot oil.
With the right framework, our clinicians, regulators, and policymakers can be confident that decisions are made using the best available science.
In October 2021, the U.S. Environmental Protection Agency (EPA) announced a PFAS Strategic Roadmap that identified research as one of
As we shared with you last week, the first paper has been published as a result of grants that were
A new critical review of existing research on per- and polyfluoroalkyl substances (PFAS) found that most PFAS studies to-date include insufficient data to draw accurate conclusions about the association of PFAS with any specific disease.
The researchers found that the most impactful studies on PFAS—those cited most often by regulators and legislators in the United States and worldwide for policy and rulemaking—lack sufficient evidence to draw accurate conclusions about the association of PFAS with any specific disease.
A new critical review of existing research on per- and polyfluoroalkyl substances (PFAS) found that most PFAS studies to-date include insufficient data to draw accurate conclusions about the association of PFAS with any specific disease.
Download this primer here. Overview Per-and polyfluoroalkyl substances (PFAS) are a group of man-made chemicals that includes the two most